Literature DB >> 1525210

Correction of mucopolysaccharidosis type I fibroblasts by retroviral-mediated transfer of the human alpha-L-iduronidase gene.

D S Anson1, J Bielicki, J J Hopwood.   

Abstract

Three retroviral constructs containing a full-length human alpha-L-iduronidase (IDUA) cDNA were made. The first, pLIdSN, is designed so that expression of the IDUA cDNA is from the 5' viral long terminal repeat (LTR). The second, pLNCId, is designed to express the IDUA cDNA from the cytomegalovirus (CMV) immediate early promoter, while in the third, pLNTId, the CMV promoter is replaced by a promoter fragment of the mouse CD45 (T200) gene. All vectors transduce resistance to G418 (neomycin). High-titer virus-producing cell lines for these constructs were made by infection of the amphotropic packaging cell line PA317 after transient expression in, and virus rescue from, the ecotropic packaging cell line psi CRE. The high-titer virus-producing cell lines were assayed for absence of helper virus, synthesis of human IDUA, and for integrity of proviral structure. Suitable lines were used as a source of virus to infect two different mucopolysaccharidosis type I (MPS I) skin fibroblast cultures. All three of the recombinant viruses corrected the enzymatic defect in MPS I fibroblasts. Surprisingly, increasing over-expression of IDUA resulted in reduced phenotypic correction of these cells as assayed by intracellular accumulation of 35S-labeled glycosaminoglycan. This was shown to be due to the induction of a phenotype analogous to mild I-cell disease in cells expressing large amounts of IDUA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525210     DOI: 10.1089/hum.1992.3.4-371

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Transcriptional control in keratinocytes and fibroblasts using synthetic ligands.

Authors:  R A Freiberg; S N Ho; P A Khavari
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

2.  Long-term in vitro correction of alpha-L-iduronidase deficiency (Hurler syndrome) in human bone marrow.

Authors:  L J Fairbairn; L S Lashford; E Spooncer; R H McDermott; G Lebens; J E Arrand; J R Arrand; I Bellantuono; R Holt; C E Hatton; A Cooper; G T Besley; J E Wraith; D S Anson; J J Hopwood; T M Dexter
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

3.  In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells.

Authors:  Valeska Lizzi Lagranha; Guilherme Baldo; Talita Giacomet de Carvalho; Maira Burin; Maria Luiza Saraiva-Pereira; Ursula Matte; Roberto Giugliani
Journal:  Metab Brain Dis       Date:  2008-09-17       Impact factor: 3.584

4.  Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.

Authors:  S E Braun; E L Aronovich; R A Anderson; P L Crotty; R S McIvor; C B Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

5.  Overexpression of N-acetylgalactosamine-4-sulphatase induces a multiple sulphatase deficiency in mucopolysaccharidosis-type-VI fibroblasts.

Authors:  D S Anson; V Muller; J Bielicki; G S Harper; J J Hopwood
Journal:  Biochem J       Date:  1993-09-15       Impact factor: 3.857

6.  Processing of iduronate 2-sulphatase in human fibroblasts.

Authors:  R Froissart; G Millat; M Mathieu; D Bozon; I Maire
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

7.  Nonviral in vivo gene transfer in the mucopolysaccharidosis I murine model.

Authors:  M Camassola; L M Braga; A Delgado-Cañedo; T P Dalberto; U Matte; M Burin; R Giugliani; N B Nardi
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.750

8.  Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I.

Authors:  Li Ou; Michael J Przybilla; Brenda L Koniar; Chester B Whitley
Journal:  Mol Genet Metab Rep       Date:  2016-08-13

9.  Clinical implementation of gene panel testing for lysosomal storage diseases.

Authors:  Alexander Gheldof; Sara Seneca; Katrien Stouffs; Willy Lissens; Anna Jansen; Hilde Laeremans; Patrick Verloo; An-Sofie Schoonjans; Marije Meuwissen; Diana Barca; Geert Martens; Linda De Meirleir
Journal:  Mol Genet Genomic Med       Date:  2018-12-11       Impact factor: 2.183

Review 10.  Mucopolysaccharidoses type I gene therapy.

Authors:  Sarah C Hurt; Patricia I Dickson; David T Curiel
Journal:  J Inherit Metab Dis       Date:  2021-07-09       Impact factor: 4.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.